# Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Study · id `cardio:ct-nct06448962` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06448962](<https://clinicaltrials.gov/study/NCT06448962>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06448962

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.

## Technical summary

Registry record NCT06448962. Randomized; double masking; primary purpose treatment. Start 2020-10-22 (actual); primary completion 2021-11-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 109 participants (enrolled count; ClinicalTrials.gov record NCT06448962, source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)
- Started: 2020-10-22 (actual) (ClinicalTrials.gov record NCT06448962, source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)
- Primary completion: 2021-11-22 (actual) (ClinicalTrials.gov record NCT06448962, source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)
- Completion: 2021-11-22 (actual) (ClinicalTrials.gov record NCT06448962, source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06448962, source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06448962-2024-06-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Condition: Hypertension, Essential
- Condition: Primary Hypercholesterolemia
- Intervention (Drug): AD-2021
- Intervention (Drug): AD-2022
- Intervention (Drug): AD-2021 Placebo
- Intervention (Drug): AD-2022 Placebo
- Lead sponsor: Addpharma Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Addpharma Inc. (`cardio:org-addpharma-inc`)

## Provenance

Content hash: 4dca2a4a453c17670f84865bdeb6dca1c165b88ca8e9df8710119d34503a088b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
